TY  - JOUR
AU  - Tomaniak, Mariusz
AU  - Chichareon, Ply
AU  - Onuma, Yoshinobu
AU  - Deliargyris, Efthymios N
AU  - Takahashi, Kuniaki
AU  - Kogame, Norihiro
AU  - Modolo, Rodrigo
AU  - Chang, Chun Ching
AU  - Rademaker-Havinga, Tessa
AU  - Storey, Robert F
AU  - Dangas, George D
AU  - Bhatt, Deepak L
AU  - Angiolillo, Dominick J
AU  - Hamm, Christian
AU  - Valgimigli, Marco
AU  - Windecker, Stephan
AU  - Steg, Philippe Gabriel
AU  - Vranckx, Pascal
AU  - Serruys, Patrick W
AU  - GLOBAL LEADERS Trial Investigators
PY  - 2019
DO  - 10.1001/jamacardio.2019.3355
UR  - https://hdl.handle.net/10668/26516
T2  - JAMA cardiology
AB  - The role of aspirin as part of antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. To evaluate the benefit and risks of aspirin in addition to ticagrelor among patients with...
LA  - en
KW  - Acute Coronary Syndrome
KW  - Aspirin
KW  - Cause of Death
KW  - Continuity of Patient Care
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Follow-Up Studies
KW  - Hemorrhage
KW  - Humans
KW  - Internationality
KW  - Male
KW  - Percutaneous Coronary Intervention
KW  - Platelet Aggregation Inhibitors
KW  - Risk Assessment
KW  - Severity of Illness Index
KW  - Survival Analysis
KW  - Tertiary Care Centers
KW  - Ticagrelor
KW  - Time Factors
KW  - Treatment Outcome
TI  - Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
TY  - research article
VL  - 4
ER  -